| abstract |
The present invention relates to novel and selective antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD as well as pain. Claimed are compounds of formula (I), wherein G and E are independently selected from among C-H or N; wherein A is a group selected from among wherein R6 is a group of the structure -L1-R13, wherein L1 is selected from among -NH-, and -N(C1-C4-alkyl)-, and wherein R13 is selected from among -C5-C6-heterocyclyl comprising 1 or 2 hetero atoms selected from among N, and 0, and wherein R13 is optionally substituted; The other variables are as defined in the claims |